Form 4: Eli Lilly Director Defers Stock Units

Eli Lilly & Co. Director Ralph Alvarez acquired and deferred 12.553 shares of common stock as stock units under the company's deferral plan.

Summary

• Director Ralph Alvarez acquired 12.553 shares of Eli Lilly & Co. common stock.
• The transaction occurred on March 16, 2026, at a price of $989.12 per share.
• These shares were deferred as stock units under the Lilly Directors' Deferral Plan.
• The stock units will be settled in shares of common stock following Alvarez's separation from service.
• Following this transaction, Alvarez directly owns 55,601.215 shares and indirectly owns 758 shares through a trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's acquisition and deferral of shares indicates confidence in the company's long-term prospects and aligns their interests with shareholders.

Positives

• Director Ralph Alvarez increased his beneficial ownership in Eli Lilly & Co. by acquiring 12.553 shares.
• The deferral of shares into stock units aligns the director's long-term interests with those of shareholders.

Risks

• The value of the deferred stock units is subject to the future performance of Eli Lilly & Co.'s common stock until settlement.

Future Outlook

The deferral of shares under the Lilly Directors' Deferral Plan indicates a long-term commitment, with settlement in common stock expected following the reporting person's separation from service.

Management Comments

• At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

StockSavvy.ai notes that director stock acquisitions, especially those involving deferral plans, are common mechanisms for aligning executive and director interests with long-term shareholder value. This transaction reflects a standard practice in corporate governance for publicly traded pharmaceutical companies like Eli Lilly.

Comparison to Industry Standards

• Director deferral plans are a common practice among S&P 500 companies, including peers in the pharmaceutical sector such as Pfizer and Johnson & Johnson, to encourage long-term commitment and align interests with shareholders.
• The acquisition of shares by a director, even if deferred, is generally viewed positively as it demonstrates confidence in the company's future prospects, similar to insider buying trends observed in other large-cap pharmaceutical firms.

Corporate Governance

Stakeholder Impact

• Shareholders: Potentially positive, as director's increased stake and deferral align interests.

Next Steps

• Settlement of deferred stock units in common stock following Ralph Alvarez's separation from service.

Key Dates

Recommendation

The acquisition and deferral of a relatively small number of shares by a director, while a positive signal of confidence, is not significant enough on its own to alter an investment thesis for a large-cap company like Eli Lilly. It reinforces a 'hold' position for investors already confident in the company's long-term strategy.

Keywords

Eli Lilly, LLY, Form 4, Insider Trading, Director Stock Acquisition, Stock Deferral Plan, Ralph Alvarez, Common Stock